Literature DB >> 31213674

Pre-market development times for biologic versus small-molecule drugs.

Reed F Beall1,2, Thomas J Hwang3, Aaron S Kesselheim3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31213674     DOI： 10.1038/s41587-019-0175-2

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Overview of the Hatch-Waxman Act and its impact on the drug development process.

Authors:  G J Mossinghoff
Journal:  Food Drug Law J       Date:  1999       Impact factor: 0.619
  1 in total
  4 in total

1.  Premarket Development Times for Innovative Vaccines--To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?

Authors:  Reed F Beall; Aaron S Kesselheim; Aidan Hollis
Journal:  Clin Infect Dis       Date:  2022-01-29       Impact factor: 9.079

Review 2.  Separation, characterization, and standardization of extracellular vesicles for drug delivery applications.

Authors:  Dominik Buschmann; Veronika Mussack; James Brian Byrd
Journal:  Adv Drug Deliv Rev       Date:  2021-05-05       Impact factor: 17.873

3.  Time to market for drugs approved in Canada between 2014 and 2018: an observational study.

Authors:  Joel Lexchin
Journal:  BMJ Open       Date:  2021-07-05       Impact factor: 2.692

4.  Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study.

Authors:  Joel Lexchin
Journal:  Int J Health Policy Manag       Date:  2021-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.